Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Large Growth in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totaling 22,107 shares, a growth of 575.0% from the May 31st total of 3,275 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 263,781 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of Barinthus Biotherapeutics

A number of hedge funds have recently made changes to their positions in BRNS. Renaissance Technologies LLC boosted its position in Barinthus Biotherapeutics by 115.8% during the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after purchasing an additional 76,800 shares during the last quarter. Rangeley Capital LLC grew its position in Barinthus Biotherapeutics by 88.8% in the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after acquiring an additional 75,024 shares in the last quarter. Finally, Baird Financial Group Inc. increased its stake in shares of Barinthus Biotherapeutics by 108.2% during the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after purchasing an additional 100,000 shares during the last quarter. 25.20% of the stock is owned by hedge funds and other institutional investors.

Barinthus Biotherapeutics Stock Performance

NASDAQ BRNS traded down $0.01 on Friday, reaching $0.71. The company’s stock had a trading volume of 703 shares, compared to its average volume of 57,080. The firm’s 50 day moving average is $0.67 and its two-hundred day moving average is $0.66. The stock has a market cap of $28.88 million, a PE ratio of -0.55 and a beta of -0.40. Barinthus Biotherapeutics has a twelve month low of $0.51 and a twelve month high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its earnings results on Thursday, April 30th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.14.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.